UPLC/Q‑TOF‑MS based plasma metabolomics and clinical characteristics of polycystic ovarian syndrome
Open Access
- 12 November 2018
- journal article
- research article
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 19 (1) , 280-292
Abstract
The present study aimed to develop novel diagnostic methods for polycystic ovarian syndrome (PCOS) by screening and identifying specific PCOS‑associated metabolic markers using plasma metabolomics. Ultra‑performance liquid chromatography/quadrapole‑time of flight‑mass spectrometry was adopted to establish the plasma metabolic fingerprint of 49 patients and 50 normal controls, in order to screen the potential metabolic markers. In addition, these markers were integrated with the clinical indexes, followed by focused analysis to obtain diagnostic markers. The present results demonstrated that not only was the concentration of palmitoyl sphingomyelin in plasma of patients with PCOS significantly increased; however, a statistically significant difference between the two PCOS subgroups was additionally demonstrated. At the same time, the concentrations of cyclic guanosine monophosphate (cGMP) and dehydroepiandrosterone sulphate in the plasma of patients of the subgroup 1 were significantly elevated. These markers were additionally integrated with the clinical index number of follicles in the left ovary and high‑density lipoprotein (HDL‑C), followed by receiver operating characteristic curve analysis, which demonstrated a diagnostic accuracy of ~90% in the control and the two subgroups. The integrated marker system consisting of palmitoyl sphingomyelin, cGMP and androsterone sulfate, as well as the number of left follicles and HDL‑C may be used for the accurate diagnosis and classification of PCOS. These results confirmed that the abnormalities in hormone metabolism and lipid metabolism disorder were primarily involved in the onset of PCOS.Keywords
This publication has 27 references indexed in Scilit:
- Metabolic profiles characterizing different phenotypes of polycystic ovary syndrome: plasma metabolomics analysisBMC Medicine, 2012
- Metabonomics Reveals Plasma Metabolic Changes and Inflammatory Marker in Polycystic Ovary Syndrome PatientsJournal of Proteome Research, 2012
- Prevalence of hyperandrogenemia in the polycystic ovary syndrome diagnosed by the National Institutes of Health 1990 criteriaFertility and Sterility, 2010
- An update on the pathogenesis, inflammation, and metabolism in hirsutism and polycystic ovary syndromeGynecological Endocrinology, 2010
- Increased Low Grade Inflammatory Serum Markers in Patients with Polycystic Ovary Syndrome (PCOS) and their Relationship to PPARγ Gene VariantsExperimental and Clinical Endocrinology & Diabetes, 2008
- Rosiglitazone treatment alleviates inflammation and improves liver function in overweight women with polycystic ovary syndrome: a randomized placebo-controlled studyFertility and Sterility, 2007
- Short‐term dehydroepiandrosterone treatment increases platelet cGMP production in elderly male subjectsClinical Endocrinology, 2006
- Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndromeGynecological Endocrinology, 2005
- A common interleukin-6 gene promoter polymorphism influences the clinical characteristics of women with polycystic ovary syndromeFertility and Sterility, 2004
- The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal womenClinical Endocrinology, 1994